Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 65, 2003, Pages 167-183

  Gerlach, M ^a,b,e   Double, K ^c   Reichmann, H ^d   Riederer, P ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Prnc of Wales Med Res Institute   (Australia)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e Klin F Kinder J   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOCRYPTINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FENOLDOPAM; HALOPERIDOL; LEVODOPA; LISURIDE; MONOAMINE OXIDASE INHIBITOR; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SULPIRIDE; ANTIPARKINSON AGENT; NEUROPROTECTIVE AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DYSKINESIA; HEADACHE; HUMAN; MOTOR DYSFUNCTION; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PLASMA HALF LIFE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; SYNCOPE; THORAX PAIN; TRANSDERMAL PATCH; VASOSPASM; ANIMAL; DISEASE COURSE; DRUG EFFECT; METABOLISM; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOPAMINE AGONISTS; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SELEGILINE;

EID: 0142010011     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0643-3_10     Document Type: Conference Paper

References (63)

1. Andén NE, Rubenson H, Fuxe K (1967) Evidence for dopamine receptor stimulation by apomorphine. J Pharm Pharmacol 19: 627-629
2. Barbeau A, Sourkes TL, Murphy GF (1962) Les catecholamines dans la maladie de Parkinson. In: de Ajuriaguerra J (ed) Monoamines et Systeme Nerveux Central. Masson & Cie, Paris, pp 247-262
3. Barone P, Bravi D, Bermejo-Pareja F, Marconi R, Kulisevski J, Malagu S, Weiser R, Rost N (1999) Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide monotherapy study group. Neurology 53: 573-579
4. Battistin L, Bardin PG, Ferro-Milone F, Ravenna C, Toso V, Reboldi G (1999) Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study. Acta Neurol Scand 99: 36-42
5. Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanineffekt bei der Parkinson-Akinese. Wien Klin Wochenschr 73: 787-788
6. Brecht HM (1998) Dopaminagonisten im Vergleich. Akt Neurol 25 [Suppl 4]: S310-316
7. Carvey PM, Pieri S, Ling ZD (1997) Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 104: 209-228
8. Cassarino DS, Fall CP, Smith TS, Bennett JP (1998) Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the Parkinsonian neurotoxin methylpyridinium ion. J Neurochem 71: 295-301
9. Clow A, Freestone C, Lewis E, Dexter D, Sandler M, Glover V (1993) The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase. Neurosci Lett 164: 41-43
10. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000) Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety 11: 58-65
11. Cotzias G, Papavasiliou PS, Fehling C (1970) Similarities between neurologic effects of L-Dopa and of apomorphine. N Engl J Med 283: 31-33
12. 3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 19: 1147-1154
13. Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 38: 1236-1239
14. Fahn S (1997) Levodopa-induced neurotoxicity. Does it represent a problem for the treatment of Parkinson's disease? CNS Drugs 8: 376-393
15. Felten DL, Felten SY, Fuller RW, Romano TD, Smalstig EB, Wong DT, Clemens JA (1992) Chronic dietary pergolide preserves nigrostriatal integrity in aged-Fischer-344 rats. Neurobiol Aging 13: 339-351
16. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O (2000) Sleep attacks and Parkinson's disease treatment. Lancet 355: 1333-1334
17. Frucht S, Rogers JD, Greeene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908-1010
18. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219-225
19. Gerlach M, Riederer P, Youdim MBH (1995) Neuroprotective therapeutic strategies: comparison of experimental and clinical results. Biochem Pharmacol 50: 1-16
20. Gerlach M, Double KL, Youdim MBH, Riederer P (2000a) Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox Res 2: 99-114
21. Gerlach M, Riederer P, Reichmann H (2000b) Präklinische und klinische Aspekte von Dopamin-Agonisten. Was ist gesichert? Nervenheilkunde 19: 53-59
22. Gille G, Rausch W-D, Hung S-T, Moldzio R, Ngyuen A, Janetzky B, Engfer A, Reichmann H (2002) Protection of dopaminergic neurons in primary culture by lisuride. J Neural Transm 109: 157-169
23. Grünblatt E, Mandel S, Berkuzki T, Youdim MBH (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov Disord 14: 612-618
24. 2 receptor expressing neurons. Neuropsychopharmacology 20: 60-80
25. 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 742: 80-88
26. Hundemer HP, Lledo A, van Laar T, Oertel WH, Schwarz J, Wolters E (2000) The safety of pergolide monotherapy in early-stage Parkinson's disease. One-year interim analysis of a 3-year double-blind, randomized study of pergolide versus levodopa. Mov Disord 15 [Suppl 3]: 115
27. Jaber M, Robinson SW, Missale C, Caron MG (1996) Dopamine receptors and brain function. Neuropharmacology 35: 1503-1519
28. Kitamura Y, Kohno Y, Nakazawa M, Nomura Y (1997) Inhibitory effects of talipexole and pramipexole on MPTP-Induced dopamine reduction in the striatum of C57BL/ 6N mice. Jpn J Pharmacol 74: 51-57
29. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr MA (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51: 1057-1062
30. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W, Welsh M, and the Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653-1661
31. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN (2001) Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 24: 163-169
32. Müngersdorf M, Sommer U, Reichmann H (1999) Therapy with high-dose ropinirole in patients with fluctuating Parkinson's disease. Eur J Neurol 6 [Suppl 3]: 132
33. Müngersdorf M, Sommer U, Sommer M, Reichmann H (2001) High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm 108: 1309-1317
34. Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12: 905-912
35. Nishibayashi S, Asanuma M, Kohno R, Gomez-Vargas M, Ogawa N (1996) Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 67: 2208-2211
36. Neusch C, Böhme V, Riesland N, Althaus M, Moser A (2000) The dopamine D2 receptor agonist alpha-dihydroergocryptine modulates voltage-gated sodium channels in the rat caudate-putamen. J Neural Transm 107: 531-541
37. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657: 207-213
38. Opacka-Juffry J, Wilson AW, Blunt SB (1998) Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum. Brain Res 810: 27-33
39. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR (2001) A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 108: 71-77
40. Parkinson Study Group (2000) Pramipexole versus levodopa as initial treatment for Parkinson's disease. JAMA 284: 1931-1938
41. Pedersen V, Double K, Riederer P, Gerlach M, Schmidt WJ (1999) Behavioral, biochemical and neurochemical effects of dopamine agonists in an animal model of Parkinson's disease. Göttingen Neurobiology Report, vol 2. Thieme, Stuttgart, Abstract No 746
42. 3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 312: 35-44
43. Przuntek H, Welzel D, Gerlach M, Blümner E, Danielczyk W, Kaiser HJ, Kraus PH, Letzel H, Riederer P, Überla K (1996) Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm 103: 699-715
44. Przuntek T, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel H (1999) SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur J Neurol 6: 141-150
45. 18F)dopa PET study. Neurology 50: A330
46. Rascol O, Brooks DJ, Korczyn AD, Deyn PP, Clarke CE, Lang AE, for the 056 Study Group (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491
47. Riederer P (1988) Biochemie dopaminerger Systeme. In: Fischer P-A, Frieling B (eds) Morbus Parkinson - neue Möglichkeiten mit Lisurid. de Gruyter, Berlin, pp 13-25
48. Rinne UK (1999) Kombinationstherapie mit Lisurid und L-Dopa in den Frühstadien der Parkinson-Krankheit verringert und verzögert die Entwicklung motorischer Fluktuationen. Nervenarzt 1 [Suppl]: S19-25
49. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 55 [Suppl 1]: 23-30
50. Runge I, Horowski R (1991) Can we differentiate symptomatic and neuroprotective effects in Parkinsonism? J Neural Transm [P-D Sect] 4: 273-283
51. 2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 19: 115-126
52. Sano I (1960) Biochemistry of the extrapyramidal system. Shinkei Kenkyu no Shimpo Adv Neurol Sci 5: 42-48
53. Schmauss C (2000) Dopamine receptors: novel insights from biochemical and genetic studies. Neuroscientist 6: 127-138
54. Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F (1998) The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 21: 169-175
55. Sharma JC, Ross IN (1999) Long term role of pergolide as an adjunct therapy in Parkinson's disease: influence on disability, blood pressure, weight and levodopa syndrome. Parkinson Relat Disord 5: 111-114
56. Stocchi F (1998) Dopamine agonists in Parkinson's disease. What is their role in early treatment? CNS Drugs 10: 159-170
57. Stocchi F, Vacca L, Berardelli A, De Pandis F, Ruggieri S (2001) Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov Disord 16: 301-305
58. The Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321: 1364-1371
59. Uitti RJ, Ahlskog JE (1996) Comparative review of dopamine receptor agonists in Parkinson's disease. CNS Drugs 5: 369-388
60. 1 receptor agonists. CNS Drugs 11: 83-91
61. Vinar O, Zapletalek M, Kazdova E, Nahunek K, Molcan J (1985) Antidepressant effects of lisuride are not different from effects of amitriptyline and nortriptyline. Activ Nerv Sup (Praha) 27: 250-251
62. Wachtel H (1999) Dopamin-Rezeptor-Agonisten: Apomorphin, Bromocriptin, Lisurid, Pergolid. In: Riederer P, Laux G, Pöldinger W (eds) Neuropsychopharmaka. Ein Therapie-Handbuch, Bd 5. Parkinsonmittel und Antidementiva, 2. Aufl. Springer, Wien New York, pp 201-225
63. Yoshikawa T, Minamiyama Y, Naito Y, Kondo M (1994) Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 62: 1034-1038